| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt","as_of":"2026-04-17T02:13:18.114675+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt","company":"SANUWAVE Health, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_0670251c8733b369","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt","content_type":"text/plain","enriched_at":"2026-04-17T08:45:30.133829+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"snwv-20260416","final_url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt","source_event_id":"evt_a1d250c8abb5","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"d1f97aabb049ec86","kind":"sec_filing","published_at":"20260416","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-16","2026-04-17T02:13:18.114675+00:00","2026-03-31","2026-03-26"],"entities":[{"asset_class":"equity","name":"SANUWAVE Health, Inc.","relevance":"high","symbol":"SNWV","type":"issuer"},{"asset_class":"equity","name":"Sanuwave Health, Inc. (the \u201cCompany\u201d)","relevance":"high","symbol":"SNWV","type":"issuer_reference"},{"asset_class":"unknown","name":"Peter Sorensen","relevance":"medium","symbol":"","type":"person"},{"asset_class":"unknown","name":"Morgan Frank","relevance":"medium","symbol":"","type":"person"},{"asset_class":"unknown","name":"Nasdaq Stock Market LLC","relevance":"low","symbol":"","type":"exchange"}],"event_type":"earnings","information_gaps":["What changed vs prior known state is not explicitly quantified in the provided text beyond stating the Q1 2026 revenue is \u201cwithin the range of guidance\u201d from the March 26, 2026 Q4 2025 earnings release; the prior exact guidance range is not reproduced here.","No additional financial metrics (e.g., gross margin, EPS, cash flow) are included in the provided excerpt.","The specific \u201cseveral good-sized deals\u201d amounts and timing are not disclosed in the provided text.","The 8-K\u2019s specific SEC Item coverage is limited to Item 2.02 and Item 9.01(d) in the excerpt; no other items are shown."],"key_facts":["Form type: 8-K (Current Report).","Date of earliest event reported: April 16, 2026.","Item 2.02: On April 16, 2026, the Company issued a press release announcing certain preliminary financial results for the quarter ended March 31, 2026; the press release is attached as Exhibit 99.1.","Item 9.01(d): Exhibit 99.1 is a press release dated April 16, 2026.","Exhibit 99.1 states preliminary revenues for Q1 2026 are expected to be $9.6 million to $9.7 million.","Exhibit 99.1 states the expected Q1 2026 revenue is an increase of 3\u20134% over Q1 2025.","Exhibit 99.1 states the expected revenue is within the range of guidance given in the Company\u2019s Q4 2025 earnings release issued on March 26, 2026.","Exhibit 99.1 includes CEO commentary that several good-sized deals slid out of the quarter and brought results toward the lower end of guidance; all referenced deals remain live.","Exhibit 99.1 includes discussion that reimbursement changes for skin substitutes and allografts caused practitioners/customers to pause or pull back in advanced wound care (contextual commentary, not quantified)."],"numeric_claims":[{"label":"Q1 2026 expected revenue (range, USD millions)","value":"$9.6\u2013$9.7 million"},{"label":"Q1 2026 revenue YoY change","value":"up 3\u20134% over Q1 2025"}],"primary_claim":"The company\u2019s Form 8-K furnished preliminary Q1 2026 revenue guidance of $9.6\u2013$9.7 million (up 3\u20134% YoY) for the quarter ended March 31, 2026.","relevance_score":0.72,"sentiment":"mixed","source_quality":"high","summary":"SANUWAVE Health, Inc. filed a Form 8-K on April 16, 2026 to furnish a press release with preliminary Q1 2026 financial results. The press release states expected Q1 2026 revenue of $9.6\u2013$9.7 million, up 3\u20134% year-over-year and within prior Q1 guidance.","topics":["Form 8-K","preliminary financial results","revenue guidance","wound care","directed energy systems","FDA-approved systems","exhibit 99.1","quarter ended March 31, 2026"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 SANUWAVE Health, Inc. \u00b7 Filed 20260416","ticker":"SNWV","tickers":["SNWV"],"title":"SNWV filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1417663/0001628280-26-025553.txt"}... |